Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 12/20 | 0.44 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 2/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30259615 | 1.00 | CFTR (0.44) | CFTRIKBKBHDAC1HDAC6PLAU | |
| SCHEMBL1711471 | 0.84 | CFTR (0.42) | CFTRHDAC1HDAC6PLAU | |
| SCHEMBL30668036 | 0.84 | CFTR (0.42) | CFTRHDAC1HDAC6PLAU | |
| SCHEMBL16505391 | 0.84 | CFTR (0.42) | CFTRIKBKBHDAC1HDAC6PLAU | |
| SCHEMBL318846 | 0.81 | CFTR (0.44) | CFTRSMN1; SMN2 | |
| SCHEMBL18293452 | 0.80 | CFTR (0.42) | CFTRIKBKBSMN1; SMN2 | |
| SCHEMBL12295752 | 0.77 | CFTR (0.57) | CFTRIKBKB | |
| SCHEMBL14067731 | 0.76 | CFTR (0.36) | CFTR | |
| SCHEMBL12687704 | 0.75 | CFTR (0.38) | CFTR | |
| SCHEMBL31751413 | 0.74 | CFTR (0.53) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-20140228363-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | PIM1, GSK3A, GSK3B | CFTR 1677/4885IKBKB 529/4885HDAC1 2832/4885 |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | CFTR 4093/4885IKBKB 195/4885HDAC1 1638/4885 |
| US-20140228363-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | CFTR 1284/4885IKBKB 130/4885HDAC1 725/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | CFTR 4093/4885IKBKB 195/4885HDAC1 1638/4885 |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | CFTR 1284/4885IKBKB 130/4885HDAC1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.